Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17596655 | 0.83 | — | — | |
| SCHEMBL2538318 | 0.80 | — | — | |
| SCHEMBL18979169 | 0.79 | LMNA (0.34) | POLB | |
| SCHEMBL322778 | 0.79 | DPP4 (0.34) | — | |
| SCHEMBL4523902 | 0.79 | DPP4 (0.34) | — | |
| SCHEMBL16600622 | 0.79 | DPP4 (0.34) | — | |
| SCHEMBL322779 | 0.79 | DPP4 (0.34) | — | |
| SCHEMBL21199645 | 0.79 | — | — | |
| SCHEMBL28305316 | 0.78 | POLB (0.32) | POLB | |
| SCHEMBL570338 | 0.78 | POLB (0.32) | POLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528818-B2 | Compositions and methods for inhibition of RAS | LEIDOS BIOMEDICAL RESEARCH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12503452-B2 | Antimicrobial compounds and methods | CURZA GLOBAL, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250270225-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | NNSA | 2025-08-28 | — | — | US | disclosed |
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | ABBVIE INC. | 2024-11-21 | — | — | US | disclosed |
| WO-2024213042-A1 | BENZO-FUSED RING COMPOUND INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-10-17 | — | — | WO | disclosed |
| US-20240300964-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. | 2024-09-12 | — | — | US | disclosed |
| EP-4373822-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | Theras Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| CN-115872996-A | Estrogen receptor degradation agent compound and preparation method and application thereof | 山东绿叶制药有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2023004102-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20130217880-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009071691-A2 | OXINDOLE DERIVATIVES AND THE USE THEREOF AS A MEDICATION | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| EP-1933830-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | Vernalis (R&D) Limited (GB) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007007057-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R & D) LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | POLB 4845/4885GABRR1 165/4885ATM 3571/4885 |
| US-20130217880-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | POLB 3032/4885GABRR1 4125/4885ATM 1557/4885 |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | POLB 108/4885GABRR1 3827/4885ATM 4286/4885 |
| US-20250270225-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | POLB 1776/4885GABRR1 1003/4885ATM 3171/4885 |
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | PTPN5, PTPN1, PTPN2 | POLB 4296/4885GABRR1 3293/4885ATM 810/4885 |
| US-20240300964-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | POLB 1776/4885GABRR1 1003/4885ATM 3171/4885 |
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | POLB 1234/4885GABRR1 862/4885ATM 3818/4885 |
| US-12528818-B2 | Compositions and methods for inhibition of RAS | KRAS, NRAS, HRAS | POLB 2275/4885GABRR1 4233/4885ATM 1051/4885 |
| US-12503452-B2 | Antimicrobial compounds and methods | MPO, NISCH, RPN2 | POLB 108/4885GABRR1 3827/4885ATM 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.